Victory Capital Management
IOBT

Victory Capital Management’s IO Biotech IOBT Stock Holding History

Victory Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-43,741
Closed -$119K – 2654
2022
Q3 		$119K Buy
+43,741
New +$162K ﹤0.01% 2447

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Victory Capital Management's IOBT Position: Q4 2022 in Review

Victory Capital Management sold out of IO Biotech (IOBT) in Q4 2022, closing a stake of 43,741 shares — an estimated $119K sold.

Victory Capital Management first reported a position in IOBT in Q3 2022 and held it in 1 quarter. The position peaked at $119K in Q3 2022. 17 funds tracked by Wall St. Rank hold IOBT as of Q4 2022.

  • Victory Capital Management reported no remaining IO Biotech position as of Q4 2022 after selling out during the quarter.
  • Victory Capital Management sold 43,741 IO Biotech shares in Q4 2022, an estimated $119K.
  • Victory Capital Management first reported a position in IO Biotech in Q3 2022 and held it in 1 quarter.
  • Victory Capital Management's IO Biotech position peaked at $119K in Q3 2022.
  • 17 funds tracked by Wall St. Rank held IO Biotech as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.